Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)

NCT07033481 is registered in ClinicalTrials.gov with EIP Pharma Inc as lead sponsor.

NCT NCT07033481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07033481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)
Lead sponsor
EIP Pharma Inc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 2, 2025
Completion date
October 31, 2026
Enrollment
20 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

nonfluent variant primary progressive aphasia (nfvppa)